Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 4Neoplasms 4Neoplasm Metastasis 3Prostatic Neoplasms, Castration-Resistant 2Prostate Cancer Metastatic 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-resistant Prostate Cancer 2Bulbo-Spinal Atrophy, X-Linked 2mCRPC 1Recurrence 1Prostatic Diseases 1Patient Preference 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-Resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1MCRPC 1Genital Diseases, Male 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

enzalutamide 2ostarine 1exemestane 1abiraterone 1Prednisolone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Bulbo-Spinal Atrophy, X-Linked × enzalutamide × Clear all
NCT06764485 2026-05-06

rechARge

Celgene

Phase 3 Recruiting
960 enrolled
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02294461 2025-10-24

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Astellas Pharma Inc

Phase 3 Completed
395 enrolled 25 charts
Genitourinary

Prostatic Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡